Bone Morphogenetic Protein Segment Analysis – By Type
Bone Morphogenetic Protein Segment Analysis – By Application
Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=504158
Report Price: $ 4500 (Single User License)
Bone Morphogenetic Protein Segment Analysis – By Geography
North America dominated the Market with major share of 40% in 2020. This is owing to growing advancement in technology, rising healthcare infrastructure and increasing R&D initiatives for the development of bone morphogenetic protein. According to National Spinal Cord Injury Center, more than 17,730 cases of spinal cord injuries occur in U.S. in 2019 that increases the growth of this market.
However, Asia Pacific is estimated to outpace all the regions by clocking the highest CAGR of 3.05% during the forecast period 2021-2026 owing to rising geriatric population and increasing research and development activities in healthcare industry.
Bone Morphogenetic Protein Market Drivers
Growing Prevalence of Minimally Invasive Procedures
Increasing sports related injuries are leading to the prevalence of minimally invasive surgeries that increases the growth of this market. Moreover, rising geriatric population and increasing number of accidents also increases the demand of minimally invasive procedures that helps to expand the growth of the Bone Morphogenetic Protein Market over 2021-2026.
Increasing Technological Development
Increasing technological development in the field of bone morphogenetic protein increases the growth of this Market. Various companies such as Stemgen s.p.a are offering technology such as hrBMP4 that increasing the growth of Bone Morphogenetic Protein Market over 2021-2026.
Covid-19 Impact:
COVID-19 pandemic had greatly impacted the growth of Bone Morphogenetic Protein Market. Owing to shut down in the manufacturing units, there is an acute shortage in the supply of raw materials that reduces the sales and reduces the growth of health care research and development and are negatively impacted the growth of this market.
Bone Morphogenetic Protein Market Challenges
High Cost of Procedure
The factors that is set to impede the growth of the Bone Morphogenetic Market are the high cost of procedure and availability of alternative treatments is set to create hurdles for the Bone Morphogenetic protein Market.
Bone Morphogenetic Protein Landscape
Product launches, acquisitions, collaboration, joint ventures, and geographical expansions are key strategies adopted by players in the Bone Morphogenetic protein Market. Bone Morphogenetic protein top 10 companies are Medtronic, Cellumed Co.,Ltd, Sigma-Aldrich Corporation, ProSpec, Ember Therapeutics, DePuy Synthesis, and Others.
Development
In September 2019, Medtronic received FDA approval for the use of Infuse bone graft that allow the usage of bone graft for Transforaminal Lumbar Interbody Fusion (TLIF) spine procedures.
Key Takeaways
Geographically, in 2020, North America dominated the Bone Morphogenetic Protein Market owing to growing advancement in technology, rising healthcare infrastructure and increasing R&D initiatives for the development of bone morphogenetic protein.
Growing prevalence of minimally invasive procedures and increasing technological development in the field of bone morphogenetic protein are likely to aid in the market growth of the Bone Morphogenetic Protein.
Detailed analysis of the Strength, Weakness, and Opportunities of the prominent manufacturers operating in the market will be provided in the Bone Morphogenetic Protein Market final report.
High cost of procedure is set to create hurdles for the Bone Morphogenetic Protein Market.
Relevant Reports:
A. Spinal Fusion Market
https://www.industryarc.com/Research/Spinal-Fusion-Market-Research-504267
B. Knee Reconstruction Market
https://www.industryarc.com/Research/Knee-Reconstruction-Market-Research-504320
For more Lifesciences and Healthcare Market reports, please click here
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Bone Morphogenetic Protein Market Size Estimated to Reach $3,700 Million by 2026
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
